PACTG P1061S: EVALUATION OF IMMUNOLOGIC MEMORY FOLLOWING PNEUMOCOCCAL, HEP B

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 P1061S是P1024《高效抗逆转录病毒治疗的HIV感染儿童常规儿科免疫接种和肺炎球菌结合疫苗免疫原性评价》的后续研究，目的是评估参与并完成P1024的HAART患者对肺炎球菌结合疫苗(PCV)和肺炎球菌多糖疫苗(PPV)、麻疹疫苗(MMR)和乙肝疫苗(HBV)的免疫记忆持久性。研究人群是在2001年6月1日至2002年3月31日期间登记参加P1024并完成最初两年研究期的艾滋病毒感染者。这包括最初参与P1024的263名受试者中的大约224名受试者。在224个科目中，预计将有大约149个科目报名。报名工作将于2006年1月18日前完成，以便在PACTG结束之前完成考察访问。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. P1061S is a follow-up substudy of P1024 "Evaluation of the Immunogenicity of Pneumococcal Conjugate Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Treated with Highly Active Antiretroviral Therapy" to evaluate the persistence of immunologic memory to pneumococcal conjugate vaccine (PCV) and pneumococcal polysaccharide vaccine (PPV), measles vaccine (MMR), and hepatitis B virus (HBV) vaccine in HIV-infected subjects on HAART who participated in, and completed, P1024. The study population is HIV-infected subjects who enrolled into P1024 between June 1, 2001 and March 31, 2002 and completed the initial two-year study period. This includes approximately 224 subjects, out of the original 263 subjects who participated in P1024. Approximately 149 subjects, out of the 224 subjects, are expected to enroll. Enrollment will be completed by January 18, 2006 to allow for the completion of study visits prior to the discontinuation of the PACTG.